Christopher Hope, MD
Sleep Medicine · Opelika, ALNPI 1275829319
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.0%), food and beverage and speaking fees — rather than concentrated in one kind of arrangement. Inspire Medical Systems, Inc. accounts for 88.3% of it on its own, with 17 other manufacturers making up the rest. Reporting peaked in 2024 at $17,134 and has fallen 50.3% since, to $8,514 in 2025.
Across 200 payments — averaging $157.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Inspire Medical Systems, Inc.$28K
- Jazz Pharmaceuticals Inc.$1K
- Harmony Biosciences LLC$948
- Vertex$285
- Axsome Therapeutics, Inc.$260
- Idorsia Pharmaceuticals US Inc$145
- plus $560 from 12 others
What the payments were for
- Consulting fees$17,02954%
- Speaking & faculty fees$4,00013%
- Travel & lodging$3,49911%
- Food & beverage$6,73121%
- Education$2491%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Inspire Medical Systems, Inc. | 54 | $27,811 |
| Jazz Pharmaceuticals Inc. | 54 | $1,497 |
| Harmony Biosciences LLC | 52 | $948 |
| Vertex | 1 | $285 |
| Axsome Therapeutics, Inc. | 11 | $260 |
| Idorsia Pharmaceuticals US Inc | 8 | $145 |
| Otsuka America Pharmaceutical, Inc. | 2 | $120 |
| Philips North America LLC | 3 | $99 |
| Fisher & Paykel Healthcare Inc | 3 | $89 |
| Eisai Inc. | 1 | $80 |
| Resmed Corp | 3 | $50 |
| Lilly USA, LLC | 2 | $37 |
| Takeda Pharmaceuticals U.S.A., Inc. | 1 | $24 |
| Lundbeck LLC | 1 | $15 |
| Abbott | 1 | $15 |
| Johnson & Johnson | 1 | $12 |
| Sunovion Pharmaceuticals Inc. | 1 | $11 |
| 3b Medical, Inc. | 1 | $9 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Inspire$24,644
- Inspire Upper Airway Stimulation System$1,991
- XYREM$125
- ABILIFY MAINTENA$112
How this compares
$31,507 in reported general payments places this provider in the 80th percentile of 28 sleep medicine providers in Alabama.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| XywavSodium,calcium,mag,pot Oxybate | 20 | $304,602 |
| BelsomraSuvorexant | 13 | $6,264 |
| Modafinil | 56 | $3,822 |
| DayvigoLemborexant | 11 | $3,523 |
| Armodafinil | 48 | $2,412 |
| Temazepam | 32 | $2,018 |
| Doxepin Hcl | 77 | $1,682 |
| Trazodone Hcl | 94 | $1,214 |
| Dextroamphetamine Sulfate | 12 | $968 |
| Dextroamphetamine Sulfate ErDextroamphetamine Sulfate | 12 | $901 |
| Ropinirole Hcl | 34 | $635 |
| Zolpidem Tartrate | 84 | $613 |
| Dextroamphetamine-AmphetamineDextroamphetamine/Amphetamine | 20 | $517 |
| Gabapentin | 60 | $455 |
| Triazolam | 12 | $447 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Eisai Inc.Dayvigo | $80 | $3,52311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 28 sleep medicine providers in Alabama.
Other sleep medicine in Opelika
- James RoyHuntsville$823K
- Michael LedetDaphne$795K
- Gordon WarnerCullman$100K
- James GeyerTuscaloosa$61K
- Ashwin AnanthFoley$57K
- Bahador TafazoliCullman$26K
- Erin OzgunBirmingham$16K
- Felix MorrisFlorence$15K
- Alan ThomasBirmingham$13K
- Darren GannuchHuntsville$7K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.